In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.<ref>{{cite web |url=http://www.medpagetoday.com/Endocrinology/Diabetes/22139 |title=Roche Halts Trials of Taspoglutide }}</ref><ref>{{cite web |url=http://www.medicalnewstoday.com/articles/200893.php |title=Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended }}</ref>
